268 related articles for article (PubMed ID: 32250304)
81. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
82. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
Gustavsson A; Cattelin F; Jönsson L
Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
[TBL] [Abstract][Full Text] [Related]
83. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
84. Predictors of Societal Costs in Dementia Patients and Their Informal Caregivers: A Two-Year Prospective Cohort Study.
Joling KJ; Schöpe J; van Hout HP; van Marwijk HW; van der Horst HE; Bosmans JE
Am J Geriatr Psychiatry; 2015 Nov; 23(11):1193-203. PubMed ID: 26238227
[TBL] [Abstract][Full Text] [Related]
85. Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany.
Michalowsky B; Thyrian JR; Eichler T; Hertel J; Wucherer D; Flessa S; Hoffmann W
J Alzheimers Dis; 2016; 50(1):47-59. PubMed ID: 26639964
[TBL] [Abstract][Full Text] [Related]
86. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study.
Leibson CL; Long KH; Ransom JE; Roberts RO; Hass SL; Duhig AM; Smith CY; Emerson JA; Pankratz VS; Petersen RC
Alzheimers Dement; 2015 Aug; 11(8):917-32. PubMed ID: 25858682
[TBL] [Abstract][Full Text] [Related]
87. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
88. Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer's disease in an administrative claims database.
Nair R; Haynes VS; Siadaty M; Patel NC; Fleisher AS; Van Amerongen D; Witte MM; Downing AM; Fernandez LAH; Saundankar V; Ball DE
BMC Geriatr; 2018 Oct; 18(1):243. PubMed ID: 30326851
[TBL] [Abstract][Full Text] [Related]
89. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
90. The impact of symptom severity on the cost of Alzheimer's disease.
Small GW; McDonnell DD; Brooks RL; Papadopoulos G
J Am Geriatr Soc; 2002 Feb; 50(2):321-7. PubMed ID: 12028215
[TBL] [Abstract][Full Text] [Related]
91. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
[TBL] [Abstract][Full Text] [Related]
92. Health Care Resource Use and Social Costs in Mild Cognitive Impairment and Mild Alzheimer's Disease.
Takechi H; Yoshino H
J Alzheimers Dis Rep; 2023; 7(1):731-738. PubMed ID: 37483328
[TBL] [Abstract][Full Text] [Related]
93. Cognitive status is a determinant of health resource utilization among individuals with a history of falls: a 12-month prospective cohort study.
Davis JC; Dian L; Khan KM; Bryan S; Marra CA; Hsu CL; Jacova P; Chiu BK; Liu-Ambrose T
Osteoporos Int; 2016 Mar; 27(3):943-951. PubMed ID: 26449355
[TBL] [Abstract][Full Text] [Related]
94. The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada.
Herrmann N; Tam DY; Balshaw R; Sambrook R; Lesnikova N; Lanctôt KL;
Can J Psychiatry; 2010 Dec; 55(12):768-75. PubMed ID: 21172097
[TBL] [Abstract][Full Text] [Related]
95. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Lamb HM; Goa KL
Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
[TBL] [Abstract][Full Text] [Related]
96. Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions.
Wimo A; Handels R; Winblad B; Black CM; Johansson G; Salomonsson S; Eriksdotter M; Khandker RK
J Alzheimers Dis; 2020; 75(3):891-902. PubMed ID: 32390617
[TBL] [Abstract][Full Text] [Related]
97. The economic impact of moderate stage Alzheimer's disease in Italy: evidence from the UP-TECH randomized trial.
Chiatti C; Furneri G; Rimland JM; Demma F; Bonfranceschi F; Cassetta L; Masera F; Cherubini A; Corsonello A; Lattanzio F;
Int Psychogeriatr; 2015 Sep; 27(9):1563-72. PubMed ID: 25874654
[TBL] [Abstract][Full Text] [Related]
98. Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis.
Lin PJ; Zhong Y; Fillit HM; Chen E; Neumann PJ
J Am Geriatr Soc; 2016 Aug; 64(8):1549-57. PubMed ID: 27295430
[TBL] [Abstract][Full Text] [Related]
99. Patients with Alzheimer's disease living at home in France: costs and consequences of the disease.
Rigaud AS; Fagnani F; Bayle C; Latour F; Traykov L; Forette F
J Geriatr Psychiatry Neurol; 2003 Sep; 16(3):140-5. PubMed ID: 12967055
[TBL] [Abstract][Full Text] [Related]
100. Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.
Kosaner Kließ M; Martins R; Connolly MP
J Prev Alzheimers Dis; 2021; 8(3):362-370. PubMed ID: 34101795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
